^
    Back
    Association details:
    Biomarker:EGFR overexpression
    Cancer:Esophageal Squamous Cell Carcinoma
    Drug:larotinib (Z650) (pan-HER inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification

    Excerpt:
    ...- Histological or cytological evidence of EGFR overexpression or gene copy number increased...
    Trial ID:
    NCT03888092
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

    Excerpt:
    ...Confirmed by the central laboratory as EGFR high expression....
    Trial ID:
    NCT04415853
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    BMC Gastroenterol
    Title:

    Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study

    Published date:
    10/23/2021
    Excerpt:
    The investigator-assessed overall response rate (ORR) was 13.7% (10/73), all responses were observed in the 350 mg group of which ORR up to 20.0% (10/50), with 10 of them having EGFR overexpression and 4 having EGFR amplification....Larotinib demonstrated promising antitumor activity and manageable safety profiles in patients with pre-treated advanced ESCC with EGFR overexpression or amplification, especially at the dose of 350 mg, which showed better efficacy and acceptable safety.
    DOI:
    https://doi.org/10.1186/s12876-021-01982-4
    Trial ID:
    NCT03888092